Search
Carboplatin Treatment Options
A collection of 1669 research studies where Carboplatin is the interventional treatment. These studies are located in the United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
769 - 780 of 1669
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Terminated
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor ce... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/25/2022
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Terminated
The primary purpose of this study is to establish the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of PDR001 when administered in combination with platinum-doublet chemotherapy and other immunooncology agent(s) in treatment naive patients with PD-L1 unselected, advanced NSCLC, and to estimate the preliminary anti-tumor activity in this patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2022
Locations: Highlands Oncology Group, Fayetteville, Arkansas +22 locations
Conditions: Non-small Cell Lung Cancer
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Completed
ABRAXANE, based on results from prior studies, is a promising drug in squamous cell carcinoma of the lung. This study will help to explore the combination of ABRAXANE and carboplatin more thoroughly in the subgroup of patients who had the best response in prior studies as well as determine whether there are any biomarkers which can predict for response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2022
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Lung Cancer
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Completed
This phase I/II trial studies how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, work in different ways... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2022
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Unknown
To evaluate the tolerability,feasibility, and efficacy of combining acalabrutinib with RICE chemotherapy as second line therapy in relapsed/refractory DLBCL patients with separate primary objectives in each of in two cohorts:
Cohort A: Hematopoeitic stem cell transplantation (HSCT) eligible patients undergoing second-line salvage chemoimmunotherapy \[Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE)\] plus acalabrutinib:.
Cohort B: Individuals not eligible for HSCT undergoing second-lin... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/20/2022
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Diffuse Large B Cell Lymphoma
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Completed
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC).
Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2022
Locations: Northwest Alabama Cancer Center, Muscle Shoals, Alabama +74 locations
Conditions: Non Small Cell Lung Cancer
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Withdrawn
The purpose of this research study is to determine the rate of local regional control at 2 years when using de-intensified chemoradiotherapy (CRT) in patients with Human Papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC). Local regional control means no recurrence of the cancer in the head or neck area. Study subjects will be enrolled into 4 groups. Group/treatment will be based on a number of factors, including smoking and drinking history.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2022
Locations: Mount Sinai Hospital, New York, New York
Conditions: Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC)
Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0
Terminated
The purpose of this study is to evaluate the side effects and effectiveness of giving standard paclitaxel chemotherapy in doses based on actual body surface area in combination with standard dosed carboplatin chemotherapy for overweight women.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/29/2022
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Gynecologic Malignancies
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
Completed
This phase I trial studies the sides effects and best dose of sapanisertib, carboplatin, and paclitaxel in treating patients with malignant solid tumors that have come back (recurrent) or do not respond to treatment (refractory). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing cells, by stopping them fr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2022
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
Completed
The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m\^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2022
Locations: Sarcoma Oncology Center, Santa Monica, California +7 locations
Conditions: Advanced Solid Neoplasm
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Terminated
The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2022
Locations: Marin Cancer Care, Greenbrae, California +78 locations
Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. G... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2022
Locations: Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California +30 locations
Conditions: Lung Cancer
769 - 780 of 1669